- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Metastases: Phase I Trial of Combination of FOLFIRI and SOM 230 (clinicaltrials.gov) - Dec 6, 2015 P1, N=16, Active, not recruiting, Trial primary completion date: Nov 2015 --> Jun 2016 Trial primary completion date: Feb 2016 --> Jun 2016
- |||||||||| Reolysin (pelareorep) / Oncolytics, Andrus Reo
Enrollment change, Trial primary completion date, Combination therapy, Metastases: Study of REOLYSIN (clinicaltrials.gov) - Dec 5, 2015 P1, N=32, Recruiting, N=96 --> 0 N=20 --> 32 | Trial primary completion date: Jun 2016 --> Dec 2016
- |||||||||| Reolysin (pelareorep) / Oncolytics, Andrus Reo
New P1 trial, PD(L)-1 Biomarker, Metastases: Study of Pembrolizumab With REOLYSIN (clinicaltrials.gov) - Dec 3, 2015 P1, N=9, Not yet recruiting,
- |||||||||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date: Second Look Laparoscopy in Colorectal Cancer (clinicaltrials.gov) - Nov 30, 2015 P2, N=140, Recruiting, Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Jun 2016
- |||||||||| leucovorin calcium / Generic mfg.
Trial termination, Trial primary completion date: A Folinic Acid Intervention for Autism Spectrum Disorders (clinicaltrials.gov) - Nov 15, 2015 P2, N=160, Terminated, Active, not recruiting --> Completed Suspended --> Terminated | Trial primary completion date: Sep 2017 --> Jun 2015; Non-compliance
- |||||||||| Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date: RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma (clinicaltrials.gov) - Nov 15, 2015 P1/2, N=47, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Aug 2015
- |||||||||| Trial primary completion date: A Phase II Study of Neoadjuvant FOLFIRINOX (clinicaltrials.gov) - Nov 14, 2015
P2, N=48, Recruiting, Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Aug 2015 Trial primary completion date: Jul 2016 --> Dec 2016
- |||||||||| ipatasertib (RG7440) / Roche
Enrollment closed, Combination therapy, Metastases: Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Nov 10, 2015 P1, N=118, Active, not recruiting, Trial primary completion date: Mar 2016 --> Oct 2016 Recruiting --> Active, not recruiting
|